UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pneumococcal pneumonia in adults

Authors
Thomas J Marrie, MD
Elaine I Tuomanen, MD
Section Editor
Daniel J Sexton, MD
Deputy Editor
Sheila Bond, MD

INTRODUCTION

Of the approximately four million cases of pneumonia each year in the United States, pneumococcus (Streptococcus pneumoniae) is the most common agent leading to hospitalization in all age groups [1]. (See "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults".)

A general overview of pneumococcal pneumonia will be presented here. The epidemiology, microbiology, diagnosis, and treatment of community-acquired pneumonia are discussed separately. (See "Diagnostic approach to community-acquired pneumonia in adults" and "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults" and "Treatment of community-acquired pneumonia in adults in the outpatient setting" and "Treatment of community-acquired pneumonia in adults who require hospitalization".)

EPIDEMIOLOGY

Prevalence in community-acquired pneumonia — S. pneumoniae has traditionally been the most common cause of community-acquired pneumonia (CAP). In the preantibiotic era, S. pneumoniae was responsible for >75 percent of cases of pneumonia [2-4]. However, more recent studies have isolated the organism in only 5 to 15 percent of cases in the United States [5-9] but in a higher proportion of cases in some other countries [2,10,11]. Factors that are likely to have contributed to the decline in S. pneumoniae as a cause of CAP in the United States include the use of pneumococcal vaccines in adults, the universal use of pneumococcal conjugate vaccines in children (leading to herd immunity), and a reduction in cigarette smoking [2,12]. The impact of pneumococcal vaccination on the incidence of pneumonia is discussed in greater detail separately. (See "Pneumococcal vaccination in adults".)

It is important to note that the rate of isolation increases when more invasive methods are used for obtaining specimens, such as transtracheal aspiration, which eliminates contaminating oropharyngeal flora; this method was used in the past but is no longer used. It is believed that many culture-negative cases are caused by pneumococcus. One factor arguing for the predominance of S. pneumoniae as a cause of CAP is that, in patients with CAP who have positive blood cultures, 58 to 81 percent of bloodstream isolates are S. pneumoniae [1,13]; however, only 7 to 10 percent of patients with CAP have positive blood cultures [1,6,13]. One group has estimated that, for every case of bacteremic pneumococcal pneumonia, there are at least three additional cases of nonbacteremic pneumococcal pneumonia [14].

Risk factors

Influenza infection — Influenza infection greatly predisposes to secondary pneumococcal pneumonia [15]. This is discussed in detail separately. (See "Clinical manifestations of seasonal influenza in adults", section on 'Secondary bacterial pneumonia'.)

                                      
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: May 30, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11:586.
  2. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371:1619.
  3. Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia, Harvard University Press, Cambridge, MA 1939.
  4. Bullowa JGM, Sommers M, Turner E. The reliability of sputum typing and its relation to serum therapy. J Am Med Assoc 1935; 105:1512.
  5. Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133:610.
  6. Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.
  7. Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67:11.
  8. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.
  9. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813.
  10. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis 2016; 62:817.
  11. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.
  12. Musher DM. Editorial Commentary: Quantitative Molecular Approach to Diagnosing Pneumonia. Clin Infect Dis 2016; 62:824.
  13. Holter JC, Müller F, Bjørang O, et al. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. BMC Infect Dis 2015; 15:64.
  14. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013; 8:e60273.
  15. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571.
  16. de Roux A, Cavalcanti M, Marcos MA, et al. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. Chest 2006; 129:1219.
  17. Bhatty M, Pruett SB, Swiatlo E, Nanduri B. Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses. Alcohol 2011; 45:523.
  18. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342:681.
  19. Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 2007; 22:62.
  20. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352:2082.
  21. Wara DW. Host defense against Streptococcus pneumoniae: the role of the spleen. Rev Infect Dis 1981; 3:299.
  22. Kobel DE, Friedl A, Cerny T, et al. Pneumococcal vaccine in patients with absent or dysfunctional spleen. Mayo Clin Proc 2000; 75:749.
  23. Fernández Guerrero ML, Ramos JM, Marrero J, et al. Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. Int J Infect Dis 2003; 7:46.
  24. Kumashi P, Girgawy E, Tarrand JJ, et al. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine (Baltimore) 2005; 84:303.
  25. Schuchat A, Broome CV, Hightower A, et al. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA 1991; 265:3275.
  26. Nuorti JP, Butler JC, Gelling L, et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182.
  27. Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1.
  28. Harboe ZB, Larsen MV, Ladelund S, et al. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users. Clin Infect Dis 2014; 59:1168.
  29. Marcus JL, Baxter R, Leyden WA, et al. Invasive Pneumococcal Disease Among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System. AIDS Patient Care STDS 2016; 30:463.
  30. Meiring S, Cohen C, Quan V, et al. HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV). PLoS One 2016; 11:e0149104.
  31. Picard C, Puel A, Bustamante J, et al. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 2003; 3:451.
  32. Twomey JJ. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132:562.
  33. Costa DB, Shin B, Cooper DL. Pneumococcemia as the presenting feature of multiple myeloma. Am J Hematol 2004; 77:277.
  34. Naveau C, Houssiau FA. Pneumococcal sepsis in patients with systemic lupus erythematosus. Lupus 2005; 14:903.
  35. Linnemann CC Jr, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA 1979; 241:2619.
  36. Amber IJ, Gilbert EM, Schiffman G, Jacobson JA. Increased risk of pneumococcal infections in cardiac transplant recipients. Transplantation 1990; 49:122.
  37. de Bruyn G, Whelan TP, Mulligan MS, et al. Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 2004; 4:1366.
  38. Elias M, Bisharat N, Goldstein LH, et al. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient. Eur J Clin Microbiol Infect Dis 2004; 23:212.
  39. Shariatzadeh MR, Huang JQ, Tyrrell GJ, et al. Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. Medicine (Baltimore) 2005; 84:147.
  40. Hoge CW, Reichler MR, Dominguez EA, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994; 331:643.
  41. Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 1991; 99:147.
  42. Romney MG, Hull MW, Gustafson R, et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis 2008; 47:768.
  43. Wong A, Marrie TJ, Garg S, et al. Welders are at increased risk for invasive pneumococcal disease. Int J Infect Dis 2010; 14:e796.
  44. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000; 181:369.
  45. Gray BM, Dillon HC Jr. Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis 1986; 5:201.
  46. Austrian R. Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 1986; 18 Suppl A:35.
  47. Greenberg D, Givon-Lavi N, Broides A, et al. The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. Clin Infect Dis 2006; 42:897.
  48. Regev-Yochay G, Raz M, Dagan R, et al. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 2004; 38:632.
  49. Hill PC, Townend J, Antonio M, et al. Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis 2010; 50:1468.
  50. Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 2005; 133:891.
  51. Yagupsky P, Porat N, Fraser D, et al. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J Infect Dis 1998; 177:1003.
  52. Borer A, Meirson H, Peled N, et al. Antibiotic-resistant pneumococci carried by young children do not appear to disseminate to adult members of a closed community. Clin Infect Dis 2001; 33:436.
  53. Schrag SJ, Peña C, Fernández J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286:49.
  54. Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998; 338:1861.
  55. Heffron R. Pneumonia. In: Pneumonia, with special reference to pneumococcus lobar pneumonia, Commonwealth Fund, New York p.1939.
  56. Yershov AL, Jordan BS, Guymon CH, Dubick MA. Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model. Eur Respir J 2005; 25:693.
  57. Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377:435.
  58. Weiser JN, Pan N, McGowan KL, et al. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998; 187:631.
  59. Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 1987; 135:869.
  60. Bergeron Y, Ouellet N, Deslauriers AM, et al. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998; 66:912.
  61. Taylor SN, Sanders CV. Unusual manifestations of invasive pneumococcal infection. Am J Med 1999; 107:12S.
  62. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157:1453.
  63. Marrie TJ, Low DE, De Carolis E, Canadian Community-Acquired Pneumonia Investigators. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology--results from a Canadian multicentre study. Can Respir J 2003; 10:368.
  64. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4:112.
  65. Zimmerman HJ, Fang M, Utili R, et al. Jaundice due to bacterial infection. Gastroenterology 1979; 77:362.
  66. Heffron R. Symptoms of lobar pneumonia in Pneumonia with special reference to pneumococcus lobar pneumonia, Harvard University Press, Cambridge 1939. p.501.
  67. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230.
  68. Potgieter PD, Hammond JM. The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia. Intensive Care Med 1996; 22:1301.
  69. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243.
  70. Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 2000; 15:638.
  71. Ioachimescu OC, Ioachimescu AG, Iannini PB. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience. Int J Antimicrob Agents 2004; 24:485.
  72. Marfin AA, Sporrer J, Moore PS, Siefkin AD. Risk factors for adverse outcome in persons with pneumococcal pneumonia. Chest 1995; 107:457.
  73. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618.
  74. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501.
  75. AUSTRIAN R, GOLD J. PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. Ann Intern Med 1964; 60:759.
  76. Musher DM, Alexandraki I, Graviss EA, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000; 79:210.
  77. Burgos J, Lujan M, Falcó V, et al. The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis 2011; 53:254.
  78. Isaacs RD. Necrotizing pneumonia in bacteraemic pneumococcal infection. Br J Dis Chest 1986; 80:295.
  79. Pande A, Nasir S, Rueda AM, et al. The incidence of necrotizing changes in adults with pneumococcal pneumonia. Clin Infect Dis 2012; 54:10.
  80. Leatherman JW, Iber C, Davies SF. Cavitation in bacteremic pneumococcal pneumonia. Causal role of mixed infection with anaerobic bacteria. Am Rev Respir Dis 1984; 129:317.
  81. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 2014; 10:e1004383.
  82. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45:158.
  83. Guiraud V, Amor MB, Mas JL, Touzé E. Triggers of ischemic stroke: a systematic review. Stroke 2010; 41:2669.
  84. Elkind MS, Carty CL, O'Meara ES, et al. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke 2011; 42:1851.
  85. Chen YG, Lin TY, Huang WY, et al. Association between pneumococcal pneumonia and venous thromboembolism in hospitalized patients: A nationwide population-based study. Respirology 2015; 20:799.
  86. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.
  87. Bates JH, Campbell GD, Barron AL, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992; 101:1005.
  88. Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.
  89. García-Vázquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164:1807.
  90. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39:165.
  91. Blaschke AJ. Interpreting assays for the detection of Streptococcus pneumoniae. Clin Infect Dis 2011; 52 Suppl 4:S331.
  92. Gutiérrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286.
  93. Rosón B, Fernández-Sabé N, Carratalà J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004; 38:222.
  94. Sordé R, Falcó V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011; 171:166.
  95. Butler JC, Bosshardt SC, Phelan M, et al. Classical and latent class analysis evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of pneumococcal pneumonia in adults. J Infect Dis 2003; 187:1416.
  96. Murdoch DR, Anderson TP, Beynon KA, et al. Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-acquired pneumonia. J Clin Microbiol 2003; 41:63.
  97. Moellering RC Jr, Swartz MN. Drug therapy: The newer cephalosporins. N Engl J Med 1976; 294:24.
  98. Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474.
  99. Deeks SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics 1999; 103:409.
  100. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33:797.
  101. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42:224.
  102. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223.
  103. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520.
  104. Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42:788.
  105. Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18:777.
  106. File TM Jr, Tan JS, Boex JR. The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective. Clin Infect Dis 2006; 42:798.
  107. Marrie TJ. Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect 1999; 14:227.
  108. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837.
  109. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107:34S.
  110. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440.
  111. Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389.
  112. Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27:1010.
  113. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182:840.
  114. Morton JB, Morrill HJ, LaPlante KL, Caffrey AR. Predictors of Mortality Among U.S. Veterans With Streptococcus Pneumoniae Infections. Am J Prev Med 2016.
  115. Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. Clin Infect Dis 2013; 56:1145.
  116. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692.